Our Corporate Culture
We are convinced that iTeos’ values are key to our success. Our single greatest asset is our people; their science, collective expertise, commitment and dedication is the foundation to iTeos’ and its goal of bringing new, curative treatments to patients.
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics has the ambition of becoming a world-class leader in the sector and is continually looking to bring life science entrepreneurs and creative scientists to iTeos to supplement our expertise and help deliver new medicines to patients. iTeos is growing significantly at this time and if you are excited about our vision and values, send your resume to email@example.com and tell us how you can contribute to the success of iTeos Therapeutics.